Wuxi Biologics (Cayman) (WXIBF) AI Stock Analysis

166 Followers

Wuxi Biologics (Cayman)

(Other OTC:WXIBF)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Integrated CDMO PlatformThe integrated service offering covers a biologic drug’s path from preclinical work through commercial supply. This broad platform can deepen customer relationships, support project progression across stages, and create opportunities for repeat service revenue as programs advance.

Negative Factors

Slowing Revenue GrowthThe sharp deceleration in annual revenue growth indicates that recent top-line expansion has become less robust than the earlier multi-year trajectory. If this persists, slower project or customer progression could limit operating leverage and reduce the pace of earnings growth.

Wuxi Biologics (Cayman) (WXIBF) vs. SPDR S&P 500 ETF (SPY)

Market Cap: $25.56B
Dividend Yield: ―
Average Volume (3M): 11.65K
Price to Earnings (P/E): 34.8
Beta (1Y): -0.15
Revenue Growth: 21.58%
EPS Growth: 21.59%
Country: US
Employees: 14,705
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Wuxi Biologics (Cayman) Business Overview & Revenue Model

Company Description

Headquartered in Wuxi, China, and established in 2014, WuXi Biologics (Cayman) Inc. delivers a comprehensive, integrated suite of services spanning the entire biologics lifecycle, from initial discovery through development to large-scale manufacturin...

Wuxi Biologics (Cayman) Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

WXIBF against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HK:1521	66Neutral	HKD 4.33B	51.11	3.02%	―	10.32%	178.23%
HK:1548	65Neutral	HKD 76.86B	-14.09	-16.23%	―	53.48%	-120.02%
HK:2315	59Neutral	HKD 19.25B	43.12	15.94%	―	48.04%	166.72%
HK:1873	52Neutral	HKD 2.76B	13.52	4.45%	―	7.38%	7.90%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HK:3759	46Neutral	HKD 87.98B	44.65	10.93%	0.77%	24.21%	19.72%

* Healthcare Sector Average

Performance Comparison

WXIBF and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
WXIBF	Wuxi Biologics (Cayman)	6.21	1.71	38.00%
HK:1548	Genscript Biotech Corporation	34.74	18.23	110.42%
HK:3759	Pharmaron Beijing Co., Ltd. Class H	29.68	5.81	24.34%
HK:1521	Frontage Holdings Corp.	2.10	1.01	92.20%
HK:1873	Viva Biotech Holdings	1.30	-0.88	-40.14%
HK:2315	Biocytogen Pharmaceuticals (Beijing) Co. Ltd. Class H	43.08	10.58	32.55%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Wuxi Biologics (Cayman) AI Stock Analysis